Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies

被引:90
作者
Cummings, JL
Street, J
Masterman, D
Clark, WS
机构
[1] Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
dementia with Lewy bodies; olanzapine psychosis; neuropsychiatric inventory; delusions; hallucinations; agitation;
D O I
10.1159/000048636
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine. Methods: This was a post hoc analysis of a subgroup of patients with DLB included in a larger double-blind, placebo-controlled, randomized parallel group trial of olanzapine for the treatment of psychosis in patients with Alzheimer's disease. Patients meeting the consensus criteria for DLB and exhibiting parkinsonism and visual hallucinations were selected from the initial study. Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). Extrapyramidal symptoms were evaluated with the Simpson-Angus scale. Results: Twenty-nine patients met the criteria for DLB; 10 were randomized to placebo, 5 received 5 mg of olanzapine, 7 received 10 mg of olanzapine and 7 received 15 mg of olanzapine. Patients with DLB treated with 5 mg of olanzapine showed significant reductions in delusions and hallucinations. Patients treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of olanzapine. There was no significant exacerbation of parkinsonian symptoms in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic toxicity did not differ among treatment groups. Conclusions:This preliminary analysis suggests that olanzapine (5 or 10 mg) reduces psychosis in patients with DLB without worsening parkinsonism. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:67 / 73
页数:7
相关论文
共 53 条
[1]  
Aarsland D, 1999, INT J GERIATR PSYCH, V14, P69, DOI 10.1002/(SICI)1099-1166(199901)14:1<69::AID-GPS888>3.0.CO
[2]  
2-C
[3]   Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: A clinicopathological study [J].
Ala, TA ;
Yang, KH ;
Sung, JH ;
Frey, WH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (01) :16-21
[4]   RISPERIDONE FOR PSYCHOTIC AND BEHAVIORAL SYMPTOMS IN LEWY BODY DEMENTIA [J].
ALLEN, RL ;
WALKER, Z ;
DATH, PJ ;
KATONA, CLE .
LANCET, 1995, 346 (8968) :185-185
[5]  
[Anonymous], 1998, Int J Geriatr Psychopharmacol
[6]  
Ballard C, 1999, AM J PSYCHIAT, V156, P1039
[7]   Neuroleptic sensitivity to clozapine in dementia with Lewy bodies [J].
Burke, WJ ;
Pfeiffer, RF ;
McComb, RD .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 1998, 10 (02) :227-229
[8]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[9]  
CHACKO RC, 1993, J NEUROPSYCH CLIN N, V5, P206
[10]  
Chandler J D, 1988, J Geriatr Psychiatry Neurol, V1, P71, DOI 10.1177/089198878800100203